GeoVax Labs, Inc. (Nasdaq: GOVX) announced it will present its lead COVID-19 vaccine candidate, GEO-CM04S1, at the Emerging Growth Conference on September 25, 2025. Chairman and CEO David Dodd will discuss recent positive interim clinical results that were highlighted at two major international scientific meetings this month.
At the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland, Phase 2 data in chronic lymphocytic leukemia (CLL) patients showed that CM04S1 achieved the study's immune response primary endpoint, while the comparator mRNA vaccine did not. Based on the Data Safety Monitoring Board's recommendation, further enrollment is proceeding exclusively in the CM04S1 arm. Additionally, interim results presented at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) 2025 in Lisbon, Portugal, demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients, with no serious adverse events reported. These data reinforce CM04S1's differentiation versus standard-of-care vaccines.
“These results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines,” said David Dodd. “Our MVA platform is demonstrating the potential to deliver broad, durable immune protection where it is needed most.”
The presentation will take place from 3:55 PM to 4:05 PM Eastern Time. Interested parties can register to attend the conference and receive event updates at this link. A replay will be made available following the event on EmergingGrowth.com and the Emerging Growth YouTube channel.
GeoVax is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in CLL patients, and a more robust booster among healthy patients who previously received mRNA vaccines. The company is also developing a vaccine targeting Mpox and smallpox and anticipates progressing directly to a Phase 3 clinical evaluation based on recent EMA regulatory guidance.
These developments highlight the importance of CM04S1 as a potential solution for immunocompromised populations who have inadequate responses to current mRNA vaccines, addressing a significant unmet medical need. The positive interim data and continued enrollment in the CM04S1 arm underscore the vaccine's promise in providing durable immune protection.
